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ABSTRACT Infectious bronchitis virus (IBV) is a
great economic burden both for productive losses and
costs of the control strategies. Many different vacci-
nation protocols are applied in the same region and
even in consecutive cycles on the same farm in order
to find the perfect balance between costs and bene-
fits. In Northern Italy, the usual second vaccination
is more and more often moved up to the chick’s first
d of life. The second strain administration together
with the common Mass priming by spray at the hatch-
ery allows saving money and time and reducing ani-
mal stress. The present work compared the different
vaccine strains (Mass-like or B48, and 1/96) kinetics
both in field conditions and in a 21-day-long experimen-
tal trial in broilers, monitoring the viral replication by
upper respiratory tract swabbing and vaccine specific
real time reverse transcription PCR (RT-PCR) quan-
tification. In both field and experimental conditions,
titers for all the vaccines showed an increasing trend
in the first 2 wk and then a decrease, though still re-
maining detectable during the whole monitored period.
IBV field strain and avian Metapneumovirus (aMPV)
presence also was also investigated by RT-PCR and se-
quencing, and by multiplex real-time RT-PCR, respec-
tively, revealing a consistency in the pathogen intro-
duction timing at around 30 d, in correspondence with
the vaccine titer’s main decrease. These findings sug-
gest the need for an accurate knowledge of live vac-
cine kinetics, whose replication can compete with the
other pathogen one, providing additional protection to
be added to what is conferred by the adaptive immune
response.
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INTRODUCTION
Infectious bronchitis virus (IBV) is an avian Gam-
macoronavirus that causes a highly contagious and ef-
fectively spreading disease, responsible for substantial
economic losses. IBV can affect young birds as a respira-
tory or renal infection, with high morbidity (100%) and
mortality rates, even over 50% when secondary infec-
tions or virulent strains occur (Jackwood, 2012). It also
has been associated with reproductive disorders, mainly
production drop and poor egg quality, as the outcome of
a reproductive tract infection (Cook et al., 2012). IBV
presents a global distribution and an extreme variabil-
ity, with more than 50 variants classified on antigenic
and genetic bases (Valastro et al., 2016), sharing around
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75 to 80% of identity in the S1 gene (Cavanagh, 2007).
The vivid necessity of controlling the disease has guided
the attention towards the optimization of vaccination
strategies. One of the pivotal points was represented by
the establishment of the protectotype concept, consist-
ing on the association of unrelated IBV vaccine strains
in an attempt to widen the conferred protection (Cook
et al., 1999). Indeed, many studies have been performed
to assess vaccine kinetics and cross-protection level pro-
moted by different vaccines, through several experimen-
tal trials, administration routes and timing, settings,
and evaluation methods, such as vaccine quantification
from tracheal swabs (Jackwood et al., 2009), ciliostasis
observation, or challenge virus detection (De Wit and
Cook, 2014; Jackwood et al., 2015).
An important adjustment has been introduced in the
broiler vaccination program by moving up the second
administration to the first d of age. Previously, the vac-
cination was usually performed at different times of
the production cycle, starting with priming on day-old
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birds (typically with Mass-based vaccines) and boost-
ing at 14 d (De Wit and Cook, 2014). The rationale
behind this approach was that a better tracheal epithe-
lium recovery between administrations, a milder vacci-
nation impact on animals with fewer adverse reactions
(De Wit and Cook, 2014), and a stronger immune re-
sponse (van Ginkel et al., 2015) were proven. Never-
theless, the earlier second vaccine supply could balance
other negative management aspects, such as irregular
animal vaccination, often causing rolling-reactions, and
prevent vaccine administration in the field, when poor
conditions or secondary pathogens are already present
(De Wit and Cook, 2014).
Above all, the extreme IBV strain variability and
heterogeneity over the different parts of the world im-
ply the need of an accurate evaluation of the vaccine
protection against every new variant and the choice of
the vaccination protocol on local epidemiologic bases
(Bande et al., 2015). Up to 2011, the Italian scenario
appeared to be dominated by the 793/B genotype, to-
gether with other less frequent strains such as QX, Mas-
sachusetts, It02, 624/I, B1648, and D274 (Taddei et al.,
2011), when the strong emergence of the QX genotype
as the most commonly detected one and the attribu-
tion of the 793/B persistence to homologous vaccina-
tion (Franzo et al., 2014) changed the epidemiologic
considerations. Updates in the epidemiological knowl-
edge have occasionally prompted the tuning of the vac-
cination approach to face these changes, most remark-
ably through the introduction of a QX homologous vac-
cine instead of the 793/B genotype to be associated
with the Mass one, even though the Mass-793/B as-
sociation is often reported to confer a wide protection
(Cook et al., 1999) against a broader strain range and
an effective protection especially towards QX strain
(Terregino et al., 2008; Sarueng et al., 2014; Awad et
al., 2016). Anyway, vaccination strategies including the
793/B genotype are still the most commonly applied,
and they are unceasingly evolving. In fact, over time,
several 793/B-based vaccines have been developed, orig-
inating from different progenitors and with different at-
tenuation processes. So, it is expected that these strains
would display different biological features that could re-
flect on their efficacy, virulence, and interaction with
other strains.
Among the several issues acting on poultry produc-
tivity, avian Metapneumovirus (aMPV) is emerging
as a growing health problem also in broiler farming
(Catelli et al., 2004), causing clinical signs as a sec-
ondary agent or even as the only detected pathogen
(Cecchinato et al., 2013a). In Italy, no vaccination is
currently employed in the control of the disease in this
sector, whereas it is more widely adopted among layers
and breeders to achieve adequate protection (Cecchi-
nato et al., 2012), with mostly live or inactivated sub-
type B-based vaccines according to the subtype B be-
ing the most prevalent field strain circulating (Catelli
et al., 2004; Cecchinato et al., 2012; Cecchinato et al.,
2013a). aMPV infection has been identified mainly in
late production stages (Cavanagh et al., 1999; Cecchi-
nato et al., 2013a), and many explanations for its de-
layed appearance have been proposed, such as a pe-
culiar slower replication of aMPV (Cook et al., 2001)
and the shared target of the upper respiratory tract ep-
ithelium, leading to an interference between aMPV and
IBV vaccine/field strain replication (Cavanagh et al.,
1999). Unfortunately, comprehensive data about aMPV
epidemiology, different IBV vaccine and pathogen in-
teractions, and the relevance of application timing are
often lacking or anecdotal.
Keeping this in mind, we performed an experimental
trial aimed to evaluate the kinetics and safety of a re-
cently commercialized 793/B based vaccine (i.e., 1/96
strain) as well as its interactions with a Mass-based vac-
cine (i.e., B48 strain), when co-administered at one d
of age. Considering that experimental settings can be
poorly representative of the actual field conditions, we
performed a parallel large-scale epidemiological study
following several farms where Mass-like and 1/96-based
vaccines were administered at one d of age. The vaccine
titer trends were monitored along the productive cycles,




Two different real time reverse transcription PCR
(RT-PCR) were validated in order to specifically de-
tect and quantify the vaccine strains used in this study.
One assay aimed to detect the Mass-like strains (i.e.,
Mass H120 strain and B48 strain CEVAC R© MASS
L, Ceva Santé Animale, Libourne, France), and the
other was specific for the 1/96 (CEVAC R© IBird, Ceva
Santé Animale, Libourne, France) one. Primers and
probes were designed on the variable regions of aligned
reference sequences (Table 1). The assays were per-
formed using SuperScript R© III Platinum R© One-Step
qRT-PCR Kit (InvitrogenTM, Carlsbad, CA, USA) on
LightCycler R© Nano Instrument (Roche, Basel, Switzer-
land). The 2 assays were validated on titrated vac-
cines (5.4 log10 EID50/mL for the Mass H120 strain,
4.1 log10 EID50/mL for the B48 strain, and 5.5 log10
EID50/mL for the 1/96 strain), accounting for the real-
time RT-PCR detecting both viable and non-viable
viral particles in vaccines, as well as in experimental
and field samples. The real-time RT-PCR limit of de-
tection (LoD) was evaluated using serial 10-fold vi-
ral RNA dilutions, performed in quadruplicate, rang-
ing from the undiluted vaccine to a final 10−7 dilu-
tion. LoD was defined as the lowest viral amount de-
tectable in at least 50% of the replicates. LoD was
10−0.49 EID50/mL for IBV 1/96, 10−0.49 EID50/mL for
the B48 strain, and 10−0.1 EID50/mL for the Mass
H120 strain. The specificity of each assay was assessed
by testing vaccine strains different from the targeted
ones. All assays showed an efficiency between 92 and
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Table 1. Primer and probe sequences designed for the study.
Primer or Probe Sequences (5′ to 3′) Direction
1/96 F CCTGGTTCAGGTTGGCATTT Sense
1/96 R ATGCACTGCCTGCATTGTTG Antisense
1/96 Probe FAM-TCTACTGCATAAGCACCCCCATG-BHQ1 Antisense
Mass F AGCAGACGCAGGTTTGGCTA Sense
Mass R TGGTTGACATCTTCGCAAGG Antisense
Mass Probe FAM-CATCTGGTTCCATAGACATCTTTGTCG-BHQ1 Antisense
103% and a coefficient of determination higher than
0.97.
Experimental Trial
Experimental Design. The experimental proce-
dures were approved by the Institutional Review Board
for Animal Research (Organismo Preposto al Benessere
Animale; O.P.B.A.) at the University of Padua. Four
groups (1 to 4) of 20 one-day-old Ross 308 chicks
were chosen from the same hatchery and breeders. An-
imals were individually marked and housed in 4 sepa-
rated rooms, under high biosecurity measures. Twenty
other animals from the same batch were blood sam-
pled to gather information about maternally derived
antibody (MDA) levels. At d one of the trial, each
group of day-old birds was vaccinated by spray vac-
cination, following the recommended procedures, with
different vaccine strains: group 1 was vaccinated with
H120 strain, group 2 with B48 strain, group 3 with both
B48 and 1/96 strains, and group 4 with 1/96 strain
only. Vaccine suspensions were titrated by the specific
real-time RT-PCR used for the study, revealing titers
of 104.99 EID50/mL for H120 strain, 103.90 EID50/mL for
B48, 103.97 EID50/mL for 1/96 strain, and 103.98 + 103.86
EID50/mL for B48+1/96, respectively. Ten animals out
of each group were randomly selected and marked on
the first d, and sampling was carried out by performing
oro-pharyngeal swabs (choanal cleft and pharynx). The
other 10 animals were not sampled but maintained to
simulate within-flock vaccine virus circulation. Swabs
were collected at different time points: 12 h and 2, 4,
7, 10, 14, 18, and 21 days. Swabs were divided into
2 pools of 5 swabs each, always including the same
animals, air-dried for 10 min to avoid bacterial and
mold growth, and then stored at -80◦C until processing.
Swabs were eluted in 2 mL of PBS, and RNA extrac-
tion was performed using the High Pure RNA Isolation
Kit (Roche, Basel, Switzerland), following the manufac-
turer’s instructions. Samples underwent both the Mass-
like and 1/96 specific real-time RT-PCR, as previously
described, for the detection of the applied vaccine and
the exclusion of a possible contamination by the other
strain.
Serology. Blood samples were obtained from 20
one-day-old Ross 308 chicks of the same origin to eval-
uate MDA levels. Infectious Bronchitis Virus Antibody
Test Kit (IDEXX, Westbrook, Maine, USA) was used
following the manufacturer’s instructions. Samples with
S/P absorbance ratios of less than or equal to 0,2 were
considered negative (corresponding to an antibody titer
of 102,60).
Field Trial
Animals and Vaccine Strains. The screening ac-
tivity focused on 70 broiler flocks distributed in North-
ern Italy and sampled over different production cycles.
All sampled animals were vaccinated on the first d of
life with 2 different IBV vaccine strains (i.e., 1/96 and
Mass-based vaccines, excluding B48 strain), following
the protectotype concept.
Samples. Samples consisted of swabs taken from the
upper respiratory tract, and sampling was arranged in
at least 2 time points of the bird life span per productive
cycle, at the beginning and at the end, for commercial
reasons, in order to monitor the presence of the vaccines
and the bird health. Ten swabs for each flock or house
were pooled, air-dried, stored at −80◦C until extraction,
and processed as previously described.
Diagnostic Assays Towards Vaccines and Field
Pathogens. All samples were tested, and IBV vaccine
amount was quantified with the 2 previously described
real-time RT-PCR. Additionally, diagnostics for IBV
field strain detection, based on a RT-PCR able to de-
tect all IBV genotypes currently circulating in Italy,
was performed on at least one sample per cycle from
the latest period (>30 d). Furthermore, whenever clin-
ical signs were reported (i.e., about 16% of the total
amount of the tested samples), related samples were
tested independently from animal age. All positive sam-
ples were sequenced to evaluate the presence of vaccine
strains and their genetic stability or the entry of a field
strain. Briefly, the generic IBV RT-PCR described by
Cavanagh et al. (1999)(Cavanagh et al., 1999) was per-
formed with minor modifications, using SuperScript R©
III One-Step RT-PCR System with Platinum R© Taq
DNA Polymerase kit (InvitrogenTM, Carlsbad, CA,
USA) on Applied Biosystems 2720 Thermal Cycler (Ap-
plied Biosystems, Foster City, CA, USA), and the am-
plicons were then sequenced using the same primers.
The sequences, encompassing the hypervariable region
of the S1 gene, were used for a phylogenetic-based clas-
sification by comparison with reference strains (Valas-
tro et al., 2016). Starting from the fourth wk of the
production cycle, when most of the aMPV detec-
tions are expected (Cecchinato et al., 2013a), samples
were systematically analyzed also for aMPV detection
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Figure 1. Vaccine titer trends relative to animal age in experimental and field conditions: titers from the experimental trial are represented by
continuous lines color-coded for each group (1 to 4); titers from the field trial are marked by red dots for Mass-like strains and by blue triangles
for 1/96 strain, and the overall trend is depicted by red and blue lines, respectively.
using a multiplex real-time RT-PCR (Cecchinato et al.,
2013b).
Database Setting. Samples were organized in a
comprehensive database of available information about
flocks, sampling time, chicken age, clinical signs, and
lab results, such as vaccine detection and titers, se-
quencing results, and aMPV positivity.
Statistical Analysis. The effect of sampling age and
genotype on vaccine viral titers was evaluated using
the robust analysis of covariance (ANCOVA) (Wilcox,
2012). This method compares the trimmed means of the
2 group (i.e., vaccine genotype) viral titers at differ-
ent time points along the covariate (i.e., sampling age).
The trimming level was set to 0.2. Two thousand boot-
strap replicates were performed to estimate the confi-
dence intervals. The effect of Mass-like and 1/96 vac-
cine viral titers in conditioning the likelihood of IBV
field strain detection was assessed using a logistic re-
gression. A similar approach was used to evaluate the
protective effect of IBV vaccines against aMPV infec-
tion. The presence of a non-random association between
IBV field strains and aMPV was investigated by a Chi-
square test. All analyses were performed using the R




Serology. MDA levels appeared to be definitely ho-
mogeneous among the sampled birds, ranging from
102,95 to 103,88 with a mean of 103,57.
Vaccine Kinetics. No cross-contamination was de-
tected among the groups, and similar viral titers be-
tween the 2 pools from the same sampling moment were
highlighted for all groups. Mean viral titers were calcu-
lated between the 2 pooled samples collected at each
time point (Figure 1). All groups were negative for the
RNA of the respective applied vaccine at 12 h post vac-
cination. At every other sampling time, all groups were
positive, except group 3, which appeared negative only
for B48 RNA until 7 d p.v. In group 1, H120 titers
showed an increase until d 7 (103.73 EID50/mL) and then
a decrease. In group 2, B48 titers displayed a peak at
d 10 (103.99 EID50/mL), reaching higher titers than the
other Mass-like strain in group 1 and presenting also a
higher titer persistence. B48 strain presented a different
behavior when administered with 1/96 strain, being un-
detectable until 7 d post vaccination with a subsequent
peak at 14 d (103.64 EID50/mL), a slight decrease at
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d 18 (102.41 EID50/mL), and a second peak at 21 d
(103.60 EID50/ml). In group 4, the maximum 1/96 RNA
viral titer has been detected at 10 d (103.28 EID50/mL),
similar to 1/96 viral titer peak in group 3 (103.26
EID50/mL at d 10), while the 2 kinetics trends re-
vealed the strain tendency to decrease when in associa-
tion with Mass-like strain and to increase again towards
d 21 when alone instead.
Field Trial
Samples. Two-hundred-forty-seven samples were
analyzed by the 2 specific real-time RT-PCR: 87.86% of
the samples were positive for 1/96 strain, while 70.05%
for Mass-like strains.
Vaccine Kinetics in Field Conditions. The vaccine
titer distribution over time revealed equally an effect
of time and genotype on viral titers. Both genotypes
displayed a positively skewed curve, with viral titers
rapidly rising during approximately the first 2 wk of life
and then progressively decreasing (Figure 1). In fact,
the few negative values for both Mass and 1/96 strains
were concentrated within the first 3 d and after the 36th
day. However, a genotype-specific significant difference
between titers was detectable, with Mass titers being
higher in the first half of the cycle but more quickly
decreasing than 1/96 titers towards the cycle end. The
detection of vaccine strain sequences was well spanned
all along the productive cycle, and the presence of iden-
tical vaccine sequences showed the genetic stability of
the used vaccines, opposite to their prolonged persis-
tence and circulation.
IBV Field Strain Detection. IBV generic RT-PCR
and sequencing were performed on 99 (40.08%) sam-
ples. The resulting sequences belonged to one of the ad-
ministered vaccines in 56 (56.57%) samples, to the QX
genotype in 22 (22.23%), to 793/B vaccine-like strains
different from 1/96 in 15 (15.16%). Five (5.06%) sam-
ples were classified as Q1 and one (1.02%) was de-
fined as a recombinant strain derived from a combi-
nation of QX and 793/B (different from 1/96 strain)
parental strains. Field strains were detected from the
35th d in correspondence with the second half of the
productive cycle and in particular with the 1/96 vaccine
titer decline, but occasionally with high Mass-like vac-
cine titers instead (Figure 2). When the relationship
between vaccine titers and field strain detection was
investigated, significantly lower 1/96 vaccine strain
titers were demonstrated in field strain positive sam-
ples compared to the negative ones. No significant
difference was demonstrated for the Mass-type vaccine
(Figure 3).
Figure 2. IBV vaccine titers in samples in which vaccine and field strain sequences were detected. Red dots represent Mass or 1/96 vaccine
sequences, while blue triangles represent field strain sequences, placed along the axes in correspondence with vaccine titers and d of age.
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Figure 3. IBV vaccine titer comparison among samples in which IBV field strain sequences and vaccine ones were detected.
aMPV Detection. Eighty-two samples (33.2%) were
tested for aMPV, and 33 (40.25%) of them were aMPV
subtype B positive. From the 35th d of the cycle, aMPV
subtype B was found frequently (Figure 4), and its pres-
ence was recognized also together with IBV field strains
(12 samples), among which 6 samples belonged to QX
genotype, even though a statistically significant asso-
ciation between aMPV and IBV infection could not
be proven. Interestingly, a tendency to display lower
IBV vaccine titers emerged in aMPV positive samples
(Figure 5), although not significant from a statistical
point of view.
DISCUSSION
The huge IBV diffusion and its extreme genetic vari-
ability produce daily challenges in the matter of control
strategies, which are mainly relying on 2 aspects: the
vaccine immunological properties and managerial as-
pects. The first ones have prompted the research and
development of vaccine combinations, providing an ef-
fective cross-protection against different strains, with
a particular focus on the locally circulating ones. Un-
fortunately, practical constraints related to economical
and organizational choices in farm management led to
a decreased vaccine efficacy compared to experimen-
tal conditions. Thus, the need for providing vaccines
able to efficiently spread in field conditions and to in-
duce good protection, even in the presence of other vac-
cines and co-infections, has led to commercialization
of new vaccine strains and to the implementation of
new administration plans, while minimizing at the same
time the number of interventions. In the current study,
the replication dynamics of different IBV vaccines co-
administered at one d of life were investigated both in
experimental and field conditions. As a matter of fact,
a strict and extended monitoring of vaccine titers could
allow verifying the vaccine administration efficacy from
a managerial point of view and also from a biological
one. In experimental conditions, viral titers displayed a
common trend characterized by a rapid increase, reach-
ing the highest values around 10 d, then decreasing un-
til the conclusion of the trial. The only exception was
represented by the behavior of B48 strain, when admin-
istered in combination with 1/96 strain, which did not
appear before d 7, and it showed a titer rise in corre-
spondence with the 1/96 expected decrease, thus tes-
tifying its persistence and replication during the early
d, even if at extremely low levels, probably due to the
prevailing 1/96 replication. The effects of this peculiar
behavior of B48–1/96 co-administration on the vaccine-
induced protection are not clear and will need further
investigations. On the contrary, 1/96 strain did not
present any major titer alteration, either by standing
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Figure 4. IBV vaccine titers in samples in which aMPV was detected.
alone or in combination with B48 strain administration,
thus supporting the inferences about the strong repli-
cation and co-replication ability of this vaccine strain
(Figure 1).
When an analogous scenario was examined in the
field, significantly overlapping results were obtained.
Similar to the experimental conditions (Figure 1), an
effect of both time and genotype was revealed on vac-
cine viral titers. Both genotypes displayed a positively
skewed curve, with viral titer rapidly rising during ap-
proximately the first 2 wk of age and then progres-
sively decreasing (Figure 1). Particularly, the few neg-
ative results were mostly located at the very beginning
of the cycle, when the viral replication could not be
homogeneous among animals and the viral spreading
could not have reached all the birds yet. In the last
phase of the cycle, negative samples were more fre-
quent, as a consequence of the generalized titer decline.
Interestingly, the differences in the 2 strain kinetics
highlighted a certain higher replication capacity for the
Mass-like strains in the upper respiratory tract at first,
opposite to the longer persistence of the 1/96 strain.
This was partially mimicked by the dynamics in ex-
perimental conditions in which H120 and B48, when
administered alone, displayed a higher titer compared
with 1/96 until d 18 and 21, respectively. The end
of the trial did not allow gathering further conclu-
sions about the following B48 titer trend; neverthe-
less, another study (Tatár-Kis et al., 2016) explored
the second half of the productive cycle of similarly
vaccinated animals: B48 appeared always lower than
1/96, which displayed a notable persistence. There-
fore, the observed pattern could be attributed to ac-
tual viral biological properties and not to the particular
scenario.
A separate discussion must be reserved to the inter-
action between the 2 vaccines. Even if presenting some
dissimilarities, both vaccine trends were quite overlap-
ping, and high viral titers were frequently encountered,
hence suggesting the absence of a competition between
the 2 genotypes, and a parallel coexistence also when
administered on the same day. This clearly conflicts
with the experimental evidences, in which an obvious
interference was observed. Two main hypotheses can be
introduced to explain this discrepancy; at first a Mass
vaccine different from B48 is currently used in Italy,
so the different biological properties of this virus could
explain its lower susceptibility to 1/96 competition. Ad-
ditionally, in field conditions, the Mass vaccine is often
provided at the hatchery, while the 1/96 is provided
upon arrival at the farm. Considering that a higher
affinity for the tracheal receptor has been proposed as a
source of the increased replication of 793/B genotypes
(Cook et al., 1999), this short lag phase between the
2 administrations could enhance the Mass vaccine cell
adhesion and replication.
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Figure 5. IBV vaccine titer comparison between aMPV negative and positive samples.
It must be stressed also that experimental trials are
often poorly representative of the sub-optimal condi-
tions found in the field, and thus they should be inter-
preted with caution.
In fact, comparing the prolonged vaccine persistence
in the field with the experimental trial trend, the ex-
perimental conditions could have influenced the viral
titers because of the small number of involved animals,
leading to a lower viral circulation. On the other hand,
a controlled environment could have minimized the risk
of other infections or the presence of stressing and im-
munosuppressive conditions, placing the premises for
unbiased results by other pathogens’ competitive ac-
tions. The abovementioned field scenario raises a ques-
tion about vaccine viral attenuation and the efficacy of
the immune response, which appears to be insufficient
for the vaccine clearance within production cycles, al-
lowing a continuous re-infection of the animals because
of a high environmental infectious burden.
However, it must be clearly stated that the prolonged
vaccine circulation could be advantageous by increas-
ing the “vaccination coverage” and granting a protec-
tive effect ascribable also to the interference against
the field strains. In fact, higher 1/96 strain titer seem
to confer better protection against field strains. Liter-
ature reports how this particular genotype, in associ-
ation with Mass vaccine administration, could ensure
strong protection against QX strain (Terregino et al.,
2008; Sarueng et al., 2014; Awad et al., 2016), which
is the most prevalent in Italy and the most detected
one in this study as well. Moreover, the frequency of
Italian QX outbreaks has been correlated to the 793/B
vaccine application, with its peaks quite explained by
the 793/B administration suspension (Franzo et al.,
2016). Afterward, a clear effect of the viral competi-
tion emerges from this study, because of the IBV field
strain occurrence mainly in the second part of the pro-
ductive cycle, when the vaccine titers are decreasing,
but the immunity should still be effective because of
the continuous stimulus imposed by vaccine circulation.
Even if the sampling nature of this study has created a
lack of information from the 22nd to the 30th d of the
cycle, due to the primary aim of assessing the vacci-
nation adequacy, the vaccine persistence, and possible
field strain infection in the case of clinical symptoms,
the viral titer trend suggested a similar decreasing be-
havior in that gap. So a slight underestimation of IBV
field strains or aMPV entrance time also could have
occurred, since their first detections from the 35th d
of the cycle on, but this finding seems to be in line
with the expected timing, especially for aMPV (Ca-
vanagh et al., 1999; Cecchinato et al., 2013a). As a
matter of fact, another proposed competing effect is the
one between IBV and aMPV (Cavanagh et al., 1999;
Cook et al., 2001; Cecchinato et al., 2013a), which
appeared to be lightened by the sporadic finding of
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aMPV and IBV field strain co-infection in the last pe-
riod of the productive cycle, whereas the paucity of
aMPV positivity in the first part of the cycle would
enforce the competitive role sustained by high IBV
vaccine titers. The tendency to detect aMPV in pres-
ence of lower IBV vaccine titer (Figure 5) seems to
support a certain interference between the 2 viruses,
potentially due to the reduction of the susceptible
cell number or to the pre-activation of the innate im-
mune response, which could hamper aMPV replication.
aMPV field relevance appears more urgent nowadays,
even though the clinical and productive impact of
this pathogen is still partially neglected. Being this
study focussed on IBV, no epidemiological conclu-
sions can be drawn on aMPV; still, its wide pres-
ence in broilers should promote more accurate sur-
veys.
Moreover, further studies will be necessary to under-
stand also if the apparent inverse relationship between
IBV vaccine titer and aMPV infection is actually due
to competition, to the vaccine kinetics itself, or to other
unconsidered factors.
CONCLUSIONS
The importance of a simple vaccine kinetics monitor-
ing through real-time RT-PCR appears evident when
the titer kinetics and vaccine persistence suggest differ-
ent evaluations about the exerted protection. The ex-
tended vaccine presence until the cycle end would more
likely propose a competitive role of the vaccines against
the field strain entry rather than a more classical im-
munity, which should assure a quicker clearance of the
vaccine strain itself. Additionally, the implications and
features of aMPV and IBV coexistence, either of vac-
cine or field nature, could be interesting and even likely
resourceful, if consciously managed. Anyway, these con-
siderations will benefit from further studies, accounting
for serology, immunity, and protection evaluations.
ACKNOWLEDGMENTS
We thank Claudio Zangrandi for providing samples
and great field expertise, essential also for the result
interpretation. We would also like to show our grati-
tude to Amelio Meini for his insights and scientific sup-
port. We thank Ceva Salute Animale (Agrate Brianza,
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